Venous Thromboembolism – Case Presentations and Discussion

Archival Presentation Notice: This article modernizes the multimedia presentation "Venous Thromboembolism – Case Presentations and Discussion: DVT Prophylaxis after TJA: New Agents on the Horizon" originally presented by Jay R. Lieberman, M.D. (Director, New England Musculoskeletal Institute; Chairman, Department of Orthopaedic Surgery, University of Connecticut Health Center). The historical Flash lecture has been reconstructed into the synchronized video slide presentation above, with the original file preserved in the digital archives (Case_Presentations_and_Discussion_Lieberman.swf).

1. High-Yield Summary

• The Dual-Threat Balance: Effective thromboprophylaxis in total joint arthroplasty (TJA) requires balancing the prevention of fatal pulmonary embolism (PE) and symptomatic deep vein thrombosis (DVT) against the devastating consequences of surgical site bleeding, wound hematoma, prolonged drainage, and catastrophic periprosthetic joint infection (PJI).
• Evolution of Pharmacotherapy: Chemoprophylaxis has transitioned from non-selective vitamin K antagonists (warfarin) requiring frequent INR titration, to injectable low-molecular-weight heparins (enoxaparin), to oral direct Factor Xa inhibitors (rivaroxaban, apixaban), and increasingly toward risk-stratified multimodal protocols anchored by low-dose aspirin.
• The RECORD Landmark Trials: The seminal RECORD 1–4 randomized controlled trials established that oral rivaroxaban (10 mg once daily) significantly reduced total venographic VTE compared with subcutaneous enoxaparin after total hip arthroplasty (THA) and total knee arthroplasty (TKA), while highlighting the critical need for meticulous postoperative wound surveillance to mitigate bleeding events.
• Multimodal Prophylaxis Standard: Modern clinical guidelines from the American Academy of Orthopaedic Surgeons (AAOS) and the American Association of Hip and Knee Surgeons (AAHKS) mandate multimodal protocols: regional neuraxial anesthesia, rapid postoperative mobilization, synchronized mechanical intermittent pneumatic compression devices (IPCD), and risk-stratified chemoprophylaxis.
• Timing and Safety Corridor: Direct oral anticoagulants (DOACs) and LMWH should not be administered prematurely; initiating chemoprophylaxis 12 to 24 hours postoperatively preserves surgical hemostasis while providing robust antithrombotic coverage.

2. Anatomy and Pathophysiology

Venous thromboembolism after major lower extremity orthopaedic reconstruction is governed by Virchow’s classic triad: venous stasis, vascular endothelial injury, and systemic hypercoagulability. Understanding the surgical and vascular anatomy of the pelvic and lower extremity venous tree is essential for identifying both the origins of thrombi and intraoperative neurovascular danger zones.

Venous Architecture of the Lower Extremity

The lower extremity venous system is divided into deep, superficial, and perforating conduits:

• Deep Venous Conduits: Paired anterior tibial, posterior tibial, and peroneal (fibular) veins drain the calf and coalesce at the popliteal fossa to form the popliteal vein. The popliteal vein ascends through the adductor hiatus (Hunter canal) to become the femoral vein (historically termed the superficial femoral vein), which joins the deep femoral vein (profunda femoris) in the femoral triangle to form the common femoral vein. The common femoral vein crosses beneath the inguinal ligament to continue as the external iliac vein.
• Muscular Sinusoids: The soleal and gastrocnemius venous plexuses serve as capacious venous reservoirs in the calf. Intraoperative muscular paralysis and immobility induce profound stasis in these sinusoids, rendering them the primary site for initial fibrin deposition and microscopic nidus formation.
• Superficial and Perforating Systems: The great saphenous vein (GSV) and small saphenous vein (SSV) connect to the deep system via valves and perforators. While isolated superficial thrombophlebitis carries a lower embolic risk, propagation through the saphenofemoral or saphenopopliteal junctions warrants immediate antithrombotic management.

Intraoperative Danger Zones and Mechanical Torsion

During total hip arthroplasty, extreme limb positioning required for femoral exposure—specifically extreme adduction, external rotation, and extension in anterior approaches, or flexion, adduction, and internal rotation in posterior approaches—kinks the common femoral and external iliac vessels against the anterior pelvic rim or retractor blades. This mechanical distortion damages delicate venous endothelium and arrests femoral venous outflow, producing local stasis and platelet-fibrin activation directly during surgery.

During total knee arthroplasty, pneumatic tourniquet inflation induces complete circulatory arrest in the limb distal to the cuff, producing progressive tissue hypoxia, endothelial distress, and systemic fibrinolytic shutdown. Tourniquet deflation subsequently triggers a transient hypercoagulable rebound with massive release of pro-thrombotic tissue factor, microparticles, and inflammatory cytokines into the systemic circulation.

3. Pathogenesis and Risk Stratification

Thrombogenesis in arthroplasty represents a multi-hit biological cascade. Thermal and mechanical trauma from intramedullary reaming, femoral broaching, and bone preparation releases bone marrow contents, methylmethacrylate monomer, tissue factor, and procoagulant microparticles into the venous circulation. This triggers the extrinsic coagulation cascade, generating thrombin bursts that convert fibrinogen to insoluble crosslinked fibrin.

Patient-Specific vs. Surgical Risk Factors

Risk stratification must distinguish between baseline patient vulnerability and procedure-specific thrombotic drivers:

• High-Risk Patient Determinants: Prior documented episode of DVT or PE (the single strongest clinical predictor, conferring a 4- to 8-fold increased recurrence risk), active or metastatic malignancy, hereditary or acquired thrombophilias (Factor V Leiden mutation, Prothrombin G20210A gene mutation, Antithrombin III deficiency, Protein C or S deficiency, Antiphospholipid antibody syndrome), advanced age (>75 years), morbid obesity (BMI > 35 kg/m²), and congestive heart failure.
• Procedure Determinants: Bilateral simultaneous total knee arthroplasty, complex revision arthroplasty with prolonged operative duration (>120 minutes), extensive pelvic reconstruction, femoral tumor resections, and prolonged postoperative immobilization carry significantly higher VTE event rates than unilateral primary procedures.

4. Natural History and Thrombus Evolution

Without thromboprophylaxis, the historical natural history of elective lower extremity arthroplasty was characterized by alarming rates of venous thrombosis. Landmark venographic surveillance studies conducted in the 1970s and 1980s revealed that asymptomatic venographic DVT occurred in 40% to 60% of patients following THA and up to 84% of patients following TKA, with fatal PE occurring in 1% to 3% of unprophylaxed patients.

The natural course of a lower extremity deep vein thrombus involves three potential pathways:

• Spontaneous Endogenous Lysis: Small, isolated distal calf vein thrombi (confined to anterior tibial, posterior tibial, or peroneal veins) frequently undergo spontaneous endogenous fibrinolysis without clinical detection or adverse sequelae.
• Proximal Propagation: Approximately 15% to 25% of untreated calf thrombi propagate proximally into the popliteal, femoral, and iliac veins. Proximal DVT carries a substantially higher risk of fragmentation and embolization into the pulmonary arterial tree.
• Pulmonary Embolism and Chronic Sequelae: Large proximal thrombi can detach as single or multiple emboli, occluding the main pulmonary arterial bifurcations (saddle embolus) or lobar branches. This leads to acute right ventricular strain, cardiogenic shock, and sudden death. In surviving patients, non-cleared thrombi cause chronic venous valve destruction, resulting in post-thrombotic syndrome (PTS) characterized by chronic edema, venous claudication, stasis dermatitis, and intractable ulceration.

5. Clinical Presentation

History and Symptom Analysis

Clinicians must maintain high index of suspicion because the symptoms of postoperative DVT are frequently masked by expected surgical pain, tourniquet-related bruising, and periarticular soft tissue swelling:

• Deep Vein Thrombosis: Progressive, dull aching or cramping fullness in the calf, popliteal space, or groin that worsens with dependency and fails to improve with elevation. Patients frequently report tightness or a “bursting” sensation when attempting to stand or initiate gait training.
• Pulmonary Embolism: Acute onset of unexplained dyspnea, tachypnea, pleuritic chest pain that exacerbates with deep inspiration, apprehension, resting tachycardia, hemoptysis, or unheralded syncope/presyncope during ambulation.

Physical Examination

Physical examination findings must be systematically evaluated and documented bilaterally:

• Asymmetric Circumference Measurement: Objective measurement of calf circumference (measured exactly 10 cm distal to the tibial tuberosity) and thigh circumference (15 cm proximal to the superior patellar pole). A difference > 3 cm compared to the asymptomatic contralateral limb strongly correlates with deep venous obstruction.
• Unilateral Pitting Edema: Soft tissue edema extending distally to the ankle and foot, demonstrating distinct pitting upon sustained digital compression.
• Deep Venous Palpation: Localized tenderness along the distribution of the deep venous system, specifically in the popliteal fossa and along the adductor canal in the medial thigh.
• Pratt’s and Homans’ Signs: Pratt’s sign (pain elicited by gentle anteroposterior compression of the relaxed calf against the tibia) is clinically superior to Homans’ sign (pain on passive ankle dorsiflexion), which has notoriously poor sensitivity (<50%) and specificity (<60%) in postoperative arthroplasty patients and can dislodge fresh, unorganized clots.
• Cardiopulmonary Signs of PE: Resting tachycardia (>100 bpm), tachypnea (>20 breaths/min), decreased oxygen saturation on room air (SpO2 < 92%), localized crackles or friction rubs, accentuated pulmonic component of the second heart sound (P2), and elevated jugular venous pressure.

6. Imaging and Diagnostic Studies

Routine surveillance ultrasound screening of asymptomatic patients following total joint arthroplasty is explicitly contraindicated by AAOS, AAHKS, and ACCP guidelines. Diagnostic investigations must be reserved strictly for symptomatic patients.

Diagnostic Modalities for Suspected DVT

Diagnostic Modalities for Suspected PE

• Computed Tomography Pulmonary Angiography (CTPA): The definitive gold standard imaging study for suspected PE. Rapidly visualizes intraluminal filling defects in main, lobar, segmental, and subsegmental pulmonary arteries while evaluating right ventricular strain (RV/LV ratio > 1.0) and alternative parenchymal etiologies (atelectasis, pneumonia, pneumothorax).
• Ventilation-Perfusion (V/Q) Scintigraphy: Indicated in patients with severe contrast allergy or acute renal insufficiency (eGFR < 30 mL/min). Demonstrates classic wedge-shaped ventilation-perfusion mismatch defects.
• Transthoracic Echocardiography (TTE): Evaluates hemodynamically unstable patients for acute cor pulmonale, right ventricular dilatation, tricuspid regurgitation, McConnel’s sign (hypokinesia of the RV free wall with sparing of the apex), or direct visualization of thrombus-in-transit.

7. Classification and Risk Scoring Systems

Standardized clinical scoring algorithms provide validated frameworks for estimating pre-test probability of venous thromboembolic disease and guiding diagnostic imaging pathways.

Two-Level Wells Score for Deep Vein Thrombosis

Clinical Stratification: Score ≥ 2: DVT Likely (immediate duplex ultrasonography indicated); Score < 2: DVT Unlikely.

Caprini Risk Assessment Model in Arthroplasty

The Caprini model assigns weighted scores to over 30 clinical and surgical risk variables. Elective total hip or knee arthroplasty inherently assigns 5 baseline points (major surgery lasting >45 minutes in a patient >40 years with bedrest), placing all primary arthroplasty patients into the “High Risk” (≥5 points) category. Additional points for prior VTE (+3), thrombophilia (+3), active cancer (+2), or age >75 (+3) re-stratify patients into the “Super-High Risk” category, requiring aggressive chemoprophylaxis rather than single-agent aspirin protocols.

8. Prevention and Treatment Algorithms

The primary paradigm of modern arthroplasty care is primary prevention via risk-stratified multimodal thromboprophylaxis. Secondary therapeutic management applies to patients with confirmed acute VTE.

Mechanical Prophylaxis Modalities

• Intermittent Pneumatic Compression Devices (IPCD): Rapid-inflation, sequential calf and thigh cuffs enhance venous peak flow velocity, prevent pooling in the soleal sinusoids, and stimulate endogenous endothelial release of tissue plasminogen activator (tPA). Must be applied immediately in the operating room or PACU and worn continuously (≥18 hours/day) throughout the inpatient hospitalization.
• Early Ambulation: Structured same-day physical therapy and mobilization activate the calf muscle pump, reduce venous stasis, and significantly lower thrombotic risk compared with bed rest.
• Graduated Compression Stockings: Provide passive gradient pressure; however, clinical trials show no significant additive risk reduction when combined with modern chemical prophylaxis and mobile IPCDs, while posing skin shear risks in elderly patients.

Pharmacological Prophylactic Agents

Contemporary Risk-Stratified Management Algorithm

• Standard-Risk Patient (Primary THA or TKA, No Personal VTE History): Multimodal mechanical compression (IPCD) + Aspirin 81 mg BID for 4–6 weeks (THA) or 2–3 weeks (TKA). Alternatively, hybrid stepped chemoprophylaxis: Rivaroxaban 10 mg daily for 5 days postoperatively, transitioned to Aspirin 81 mg BID through postoperative day 30–35 (EPCAT II protocol).
• High-Risk Patient (Prior VTE, Active Malignancy, Known Thrombophilia, BMI > 40): Multimodal mechanical compression (IPCD) + Direct Factor Xa inhibitor (Rivaroxaban 10 mg daily or Apixaban 2.5 mg BID) or Enoxaparin (40 mg SC daily) for full extended duration (35 days for THA; 14–21 days for TKA).
• Active Therapeutic VTE Management: Confirmed proximal DVT or hemodynamically stable PE requires therapeutic-dose anticoagulation (Rivaroxaban 15 mg BID for 21 days followed by 20 mg once daily, or Apixaban 10 mg BID for 7 days followed by 5 mg BID) for a minimum of 3 months. In the presence of acute bleeding from the surgical wound, an retrievable inferior vena cava (IVC) filter is indicated as a temporary bridge until anticoagulation can be safely resumed.

9. Outcomes and Clinical Efficacy

Modern multimodal thromboprophylaxis protocols have reduced the incidence of symptomatic VTE and fatal pulmonary embolism to historical lows across major arthroplasty registries and clinical trials:

• Symptomatic VTE Rates: In contemporary series employing multimodal protocols, the 90-day incidence of symptomatic DVT ranges from 0.5% to 1.5%, with symptomatic non-fatal PE occurring in 0.2% to 0.5% of primary hip and knee arthroplasty patients.
• Fatal PE Rates: The incidence of fatal PE has plummeted from historical benchmarks of 1%–3% in the pre-prophylaxis era to less than 0.05% in modern prospective cohorts.
• The EPCAT II Landmark Findings: The multicenter EPCAT II randomized controlled trial demonstrated that in patients undergoing THA or TKA who received an initial 5-day course of rivaroxaban, subsequent extended prophylaxis with low-dose aspirin (81 mg daily) was statistically non-inferior to continued rivaroxaban (10 mg daily) for the prevention of symptomatic VTE (0.64% vs 0.70%, P < 0.001 for non-inferiority), with identical major bleeding rates (0.47% vs 0.29%).

10. Complications and Safety Profile

The safety profile of chemical thromboprophylaxis is governed by the delicate equilibrium between antithrombotic potency and surgical hemostasis. The surgical consequences of excessive anticoagulation in orthopaedics are uniquely perilous.

11. Pearls and Pitfalls

Surgical Pearls

• The 12-Hour Initiation Window: Delaying the initial dose of oral Factor Xa inhibitors (rivaroxaban, apixaban) or LMWH until 12 to 24 hours postoperatively dramatically reduces postoperative wound drainage and surgical site hematoma formation without compromising antithrombotic efficacy.
• Tranexamic Acid (TXA) Synergy: Routine intravenous or topical administration of tranexamic acid during arthroplasty provides profound antifibrinolytic hemostasis at the surgical site without increasing systemic venous thromboembolism rates, providing a safer baseline for subsequent chemoprophylaxis.
• Compliance Verification: Inpatient nursing protocols must mandate real-time verification of mechanical IPCD compliance; devices removed for physical therapy or transfers must be reapplied immediately upon return to bed.

Diagnostic and Clinical Pitfalls

• Pitfall: Ordering D-Dimer in the Acute Postoperative Window: D-dimer is uniformly elevated due to surgical trauma and bone remodeling. Ordering a D-dimer test within 4 weeks of surgery generates false-positive results that trigger unnecessary imaging and clinical confusion.
• Pitfall: Over-Treating Asymptomatic Distal Thrombi: Ordering routine screening ultrasounds detects small, self-limiting muscular calf vein thrombi. Initiating aggressive therapeutic anticoagulation for asymptomatic distal clots exponentially increases major wound complications and hematomas without improving survival.
• Pitfall: Dismissing Persistent Wound Drainage: A wound draining serosanguinous fluid beyond postoperative day 3 in a patient on aggressive Factor Xa inhibitors or LMWH must never be managed by “watching and waiting.” The anticoagulant should be immediately held or de-escalated to low-dose aspirin to prevent full-thickness skin breakdown and secondary periprosthetic infection.

12. Clinical Controversies

The field of orthopaedic thromboprophylaxis has historically been characterized by spirited philosophical and methodological debate between orthopaedic surgical consensus and medical/hematological guidelines:

The AAOS vs. ACCP Philosophical Divide

For decades, guidelines issued by the American College of Chest Physicians (ACCP) prioritized the complete eradication of all deep vein thrombosis, heavily weighting asymptomatic venographic clots as surrogate endpoints. Consequently, ACCP guidelines advocated for aggressive pharmacologic anticoagulation (LMWH, synthetic pentasaccharides, or DOACs) for all patients, viewing bleeding complications as secondary and medically manageable.

In contrast, guidelines established by the American Academy of Orthopaedic Surgeons (AAOS) and the American Association of Hip and Knee Surgeons (AAHKS) focus on preventing clinically relevant, patient-centered endpoints: symptomatic PE, fatal PE, and symptomatic proximal DVT. Orthopaedic surgeons emphasize that in major joint arthroplasty, excessive pharmacologic anticoagulation produces profound morbidity—periarticular hematomas, persistent wound drainage, re-operation, arthrofibrosis, and catastrophic deep periprosthetic joint infection (PJI) requiring two-stage revision. Modern international consensus increasingly favors the orthopaedic paradigm: multimodal mechanical prophylaxis combined with risk-stratified chemoprophylaxis, reserving aggressive DOACs for high-risk patients while validating aspirin for standard-risk cohorts.

The Next Frontier: Factor XI and XIa Inhibitors

The next major frontier in thromboprophylaxis focuses on the contact activation pathway. Factor XI and XIa inhibitors (such as abelacimab, milvexian, and osocimab) decouple pathological thrombosis from physiological hemostasis. Early phase II and III clinical trials in total knee arthroplasty demonstrate that selective Factor XI inhibition achieves potent antithrombotic efficacy with significantly lower bleeding risk compared to Low-Molecular-Weight Heparins, representing the potential “holy grail” of perioperative anticoagulation.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty (RECORD1). N Engl J Med. 2008. doi:10.1056/NEJMoa0800374 [Level I: Randomized Controlled Trial]
• Kakkar AK, Brenner B, Dahl OE et al. Extended Duration Rivaroxaban versus Short-Term Enoxaparin for the Prevention of Venous Thromboembolism after Total Hip Arthroplasty (RECORD2). Lancet. 2008. doi:10.1016/S0140-6736(08)60880-6 [Level I: Randomized Controlled Trial]
• Lassen MR, Ageno W, Borris LC et al. Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty (RECORD3). N Engl J Med. 2008. doi:10.1056/NEJMoa076016 [Level I: Randomized Controlled Trial]
• Turpie AG, Lassen MR, Davidson BL et al. Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty (RECORD4). Lancet. 2009. doi:10.1016/S0140-6736(09)60734-0 [Level I: Randomized Controlled Trial]
• Anderson DR, Dunbar M, Murnaghan J et al. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty (EPCAT II). N Engl J Med. 2018. doi:10.1056/NEJMoa1712746 [Level I: Randomized Controlled Trial]
• Matharu GS, Kunutsor SK, Judge A et al. Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2020. doi:10.1001/jamainternmed.2019.6108 [Level I: Systematic Review / Meta-Analysis]
• Lieberman JR, Pensak ML. Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty. J Bone Joint Surg Am. 2013. doi:10.2106/JBJS.L.01328 [Level V: Expert Instructional Review / Clinical Consensus]
• Lieberman JR. The New AAOS Clinical Practice Guidelines on Venous Thromboembolic Prophylaxis: How to Adapt Them to Your Practice. J Am Acad Orthop Surg. 2011. doi:10.5435/00124635-201112000-00001 [Level V: Clinical Practice Guideline / Consensus]

15. Master Class Pro-Tip

Master Class Surgical Pearl: Individualized Risk-Bleed Equilibrium: In total joint arthroplasty, never treat venous thromboembolism prophylaxis as a generic checklist. Every patient exists on a dynamic spectrum between thrombotic catastrophe and surgical hematoma. For the standard-risk patient, multimodal therapy combining intravenous tranexamic acid, continuous intraoperative and postoperative mechanical compression, and stepped aspirin chemoprophylaxis provides the optimal safety margin. When a high-risk patient mandates potent Factor Xa inhibition, delay the initial dose until 12 to 24 hours postoperatively, verify dry wound dressings before hospital discharge, and treat any drainage persisting beyond postoperative day 3 as an immediate signal to withhold anticoagulation before a sterile hematoma converts into a deep periprosthetic joint infection.

Master Class Surgical Pearl: Venous Thromboembolism Prophylaxis in Total Joint Arthroplasty